Tag:

chronic kidney disease

Latest Headlines

Latest Headlines

AstraZeneca looks to China for kidney disease R&D

AstraZeneca has struck up a partnership with the Shenzhen University Health Science Center in Shanghai to collaborate on preclinical work for chronic kidney disease treatments, a growing problem among China's aging population. 

La Jolla soars as kidney drug impresses in Phase II, but dosing questions linger

La Jolla Pharmaceutical's chronic kidney disease drug hit its primary endpoint of improving organ function in a Phase II trial, the company said, and while the results sent the biotech's shares skyward by 75%, a quirk in dosing gave some analysts pause.

Sanofi grabs a discovery pact with gut expert Ardelyx in $198M deal

There's no word on the upfront, but Sanofi has committed to pay up to $198 million in milestones if the portfolio delivers an approved therapy that can be used to treat hyperphosphatemia, a condition characterized by elevated levels of phosphate in the blood of patients with end stage renal disease and other forms of chronic kidney disease.

Relypsa pitches $126M IPO as lead CKD drug nears moment of PhIII truth

Just weeks away from reporting key endpoint data from a Phase III trial of its lead therapy, Relypsa has mapped out plans to go public, shooting for a $126.5 million payday to help complete a prospective transformative leap into marketing.

UPDATED: Rockwell Medical surges on more promising PhIII data for iron-delivery drug

Rockwell Medical shares surged early today after the biotech announced that its second, duplicate Phase III study for a new iron-delivery drug hit its primary and secondary endpoints, setting the stage for a new drug application.

AstraZeneca commits $815M to partner with FibroGen on anemia drug

AstraZeneca CEO Pascal Soriot has taken another step forward in his turnaround campaign, committing $350 million in cash and up to $465 million in milestones to partner up with FibroGen as it positions a lead anemia drug for late-stage trials.

Takeda, Affymax nail supply deal for Omontys anemia drug

Takeda Pharmaceuticals and Affymax ($AFFY) have sewn up another supply deal for their anemia drug Omontys. DSI Renal, one of the largest dialysis providers in the U.S., agreed to adopt Omontys to treat their patients with chronic kidney disease.

Kidney problems tag development delays?

Malformed kidneys in newborn babies could be markers for mental illness and problems with behavior and understanding.

AstraZeneca strikes $272M deal for Ardelyx kidney drug

Under the new partnership, Adelyx gets $35 million up front, plus up to $237.5 million in milestones, provided the RX5791 drug makes it to market.

AstraZeneca bags PhIIb-ready CKD drug in $272M Ardelyx partnership

A deal-hungry AstraZeneca has bagged a Phase IIb-ready compound for chronic kidney disease in a $272 million deal with Fremont, CA-based Ardelyx. The pharma giant agreed to pay $35 million upfront to partner on Ardelyx's lead drug, RDX5791, which spurs the body to bypass vulnerable kidneys when it flushes sodium.